New Delhi, April 11 (IANS). In line with the vision of making India a global pharma innovation hub, the ‘India Pharma 2026’ program aims to transform the sector from a mere production-based model to a value and innovation-based global powerhouse. According to an official statement issued on Saturday, this initiative will play an important role in accelerating the rapid transformation and growth of India’s pharmaceutical sector.
The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers is going to organize the 9th edition of ‘India Pharma 2026’ on 13-14 April in collaboration with FICCI and Indian Pharmaceutical Alliance. This program will be inaugurated by Union Minister JP Nadda and Minister of State Anupriya Patel.
According to the ministry, the conference will serve as an important platform for sector development and international collaboration, with a special focus on India’s pharma capacity, research and development (R&D) and strengthening global supply chains.
The theme of the event is ‘Discover in India: Leapfrogging Life-Sciences Innovation’, highlighting the role of life sciences in expanding access to healthcare, driving economic growth and strengthening the global health system.
India is already playing an important role in supplying affordable and high quality medicines to the world. Taking this strong foundation forward, ‘India Pharma 2026’ aims to give a new direction to this sector so that India can become an innovation-driven pharma powerhouse at the global level.
This program will see a large participation of policy makers, industry leaders and experts from the pharma sector. Prominent personalities include Manoj Joshi, Punya Salila Srivastava and Vinod K. Paul is involved. Apart from this, experts like Renu Swaroop and Shivkumar Kalyanaraman will also participate in it.
The two-day event will include a total of six plenary sessions along with special sessions like the ‘Start-up Showcase’, which will provide an opportunity for in-depth discussions on the future and new possibilities of the pharma sector.
–IANS
DBP
